221 Longwood Avenue
Ste. 122
Boston, MA 02115
www.AllianceFoundationTrials.org

AFT-57 / Randomized phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC

ClinicalTrials.gov Identifier: NCT05798663

Schema



Non-surgical Candidate considerations:

- Multiple nodal stations
- N3 nodes
- Bulky nodes

Key Eligibility Criteria:

- Histologically confirmed stage III NSCLC per AJCC v8
- ECOG PS 0-1
- Adequate organ function
- No active immunologic disorder
- No active other malignancy
- No contraindication to chemotherapy, immunotherapy, thoracic radiation

Study Status

- 21 selected sites out of 25
- 5 sites active
- 3 participants enrolled
- First subject first visit: December, 2024
- Expected last participant first visit: January, 2026

Objectives

Primary: Progression-free survival (PFS)

Secondary: Overall survival (OS), overall response (ORR) and safety

Principal Translational Science: Assess immunologic markers including PD-L1 to develop biomarkers for efficacy and toxicity.

The predecessor AFT-16 trial of neoadjuvant atezolizumab in this setting provided proof of concept for safety of the neoadjuvant approach and for outcomes that compare favorably with standard of care therapy.

Progression-Free and Overall Survival and Exploratory Analysis of the Patients Who Completed Concurrent Chemoradiation Therapy (CRT)



Shading indicates the 95% CI; tick marks, survival time censored. NE indicates not evaluable

JAMA Oncol. 2024;10(9):1212-1219. doi:10.1001/jamaoncol.2024.1897 Published online July 25, 2024.

Key Contacts

Study Team Project Inbox: aft57@alliancefoundationtrials.org

Study Chair Helen Ross, MD: helen_ross@rush.edu

Executive Officer David Kozono, MD: DKOZONO@bwh.harvard.edu